KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Retained Earnings (2016 - 2025)

Teva Pharmaceutical Industries' Retained Earnings history spans 17 years, with the latest figure at -$13.8 billion for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 9.3% year-over-year to -$13.8 billion, compared with a TTM value of -$13.8 billion through Dec 2025, up 9.3%, and an annual FY2025 reading of -$13.8 billion, up 9.3% over the prior year.
  • Retained Earnings for Q4 2025 was -$13.8 billion at Teva Pharmaceutical Industries, down from -$2.5 billion in the prior quarter.
  • The five-year high for Retained Earnings was -$85.0 million in Q4 2021, with the low at -$15.2 billion in Q4 2024.
  • Average Retained Earnings over 5 years is -$7.8 billion, with a median of -$7.1 billion recorded in 2021.
  • Biggest YoY gain for Retained Earnings was 96.65% in 2022; the steepest drop was 2857.65% in 2022.
  • Tracing TEVA's Retained Earnings over 5 years: stood at -$85.0 million in 2021, then crashed by 2857.65% to -$2.5 billion in 2022, then increased by 5.17% to -$2.4 billion in 2023, then tumbled by 536.45% to -$15.2 billion in 2024, then grew by 9.3% to -$13.8 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Retained Earnings are -$13.8 billion (Q4 2025), -$2.5 billion (Q3 2025), and -$14.7 billion (Q2 2025).